NEW YORK (GenomeWeb News) – Strategic Diagnostics will collaborate with the University of Delaware and the Helen F. Graham Cancer Center to develop protein biomarkers that could be used to detect metastasis in prostate cancer patients, the company said on Thursday.
SDI said it will work with UD to develop antibodies that identify protein molecule fragments that break away from primary tumors when cancer is spreading. Diagnostic tests using these antibodies could help doctors determine the stage and the severity of the cancer, and could help them develop effective treatment options specifically for metastasized cancer cases.
SDI President and CEO Francis DiNuzzo said in a statement that the company will use its Genomic Antibody Technology to develop the biomarker tests.
Further terms of the alliance were not disclosed.
The Helen F. Graham Cancer Center is one of 14 National Cancer Institute centers in the US.